Stockscreener 앱 받기
76.33
1.14%
-0.88
전일 마감가:
$77.21
열려 있는:
$77.145
하루 거래량:
3.02M
Relative Volume:
1.31
시가총액:
$12.36B
수익:
$705.14M
순이익/손실:
$-453.90M
주가수익비율:
-25.11
EPS:
-3.04
순현금흐름:
$-551.29M
1주 성능:
-4.94%
1개월 성능:
-2.60%
6개월 성능:
+78.47%
1년 성능:
+136.46%
1일 변동 폭
$74.49
$78.00
1주일 범위
$74.49
$82.57
52주 변동 폭
$23.95
$86.15
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
명칭
Ionis Pharmaceuticals Inc
전화
(760) 931-9200
주소
2855 GAZELLE COURT, CARLSBAD, CA
IONS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
76.33 | 12.51B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-09-26 | 업그레이드 | Goldman | Sell → Neutral |
| 2025-09-03 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-04-07 | 개시 | H.C. Wainwright | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Neutral |
| 2024-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | 재개 | Jefferies | Buy |
| 2024-06-14 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 개시 | Raymond James | Strong Buy |
| 2023-07-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-06-07 | 재개 | Piper Sandler | Overweight |
| 2023-05-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2022-12-21 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 재개 | Morgan Stanley | Overweight |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-01 | 개시 | Citigroup | Sell |
| 2022-03-01 | 개시 | Guggenheim | Buy |
| 2022-02-01 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-14 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | 업그레이드 | UBS | Sell → Neutral |
| 2021-03-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 개시 | UBS | Sell |
| 2020-12-15 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-09-02 | 개시 | The Benchmark Company | Hold |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-11-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 재확인 | Stifel | Hold |
| 2018-08-07 | 재확인 | Stifel | Hold |
| 2018-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 재개 | Goldman | Sell |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-08-09 | 재확인 | Stifel | Hold |
| 2017-03-10 | 다운그레이드 | Goldman | Neutral → Sell |
| 2016-12-28 | 재확인 | BMO Capital Markets | Outperform |
| 2016-12-27 | 재확인 | Leerink Partners | Mkt Perform |
모두보기
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Spinal Muscular Atrophy Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme - Barchart.com
Insider Trends: Does Ionis Pharmaceuticals Inc have consistent dividend growthJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Revenue Check: Can Ionis Pharmaceuticals Inc scale operations efficiently2025 Institutional Moves & Low Risk High Reward Ideas - baoquankhu1.vn
JPM26: Tryngolza set to become first wholly owned Ionis blockbuster - Yahoo Finance
CEO Change: Can Ionis Pharmaceuticals Inc outperform in the next rally2025 Pullback Review & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Assessing Ionis Pharmaceuticals (IONS) Valuation After A Strong 1 Year Shareholder Return - Yahoo Finance
Trend Recap: Why retail investors favor Ionis Pharmaceuticals Inc. stockJuly 2025 Setups & Long-Term Capital Growth Strategies - Bộ Nội Vụ
How reliable is Ionis Pharmaceuticals Inc. (ISI) stock dividend growthSector Rotation Strategies & Free Unmatched Market Performance - bollywoodhelpline.com
Lobbying Update: $60,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts - The Joplin Globe
Precision Trading with Ionis Pharmaceuticals Inc. (IONS) Risk Zones - Stock Traders Daily
Ionis Pharmaceuticals (IONS) Stock Analysis: Biotech Innovator with 12.69% Upside Potential - DirectorsTalk Interviews
Will Ionis Pharmaceuticals Inc. stock outperform international peersBull Run & Weekly Watchlist for Hot Stocks - Улправда
Ionis Pharmaceuticals EVP Devers sells $3.7m in shares By Investing.com - Investing.com Nigeria
Insider Sell Alert: Shannon Devers Sells 44,199 Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 44,199 Shares of Stock - MarketBeat
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
Ionis chalks up rare disease win with zilganersen - The Pharma Letter
How resilient is Ionis Pharmaceuticals Inc. stock in market downturns2025 Price Action Summary & Weekly Stock Breakout Alerts - Улправда
Will Ionis Pharmaceuticals Inc. (ISI) stock benefit from infrastructure billEarnings Recap Report & Accurate Buy Signal Alerts - Улправда
Momentum Shift: Will Ionis Pharmaceuticals Inc. stock gain from government policiesJuly 2025 Analyst Calls & Expert Verified Stock Movement Alerts - Улправда
Will Ionis Pharmaceuticals Inc. stock recover faster than peersEntry Point & Daily Risk Controlled Trade Plans - ulpravda.ru
Book value per share of Ionis Pharmaceuticals, Inc. – SWB:ISI - TradingView — Track All Markets
How Ionis Pharmaceuticals Inc. stock compares to industry benchmarksGap Down & Technical Pattern Based Buy Signals - ulpravda.ru
Can Ionis Pharmaceuticals Inc. stock sustain market leadershipTrade Entry Summary & Community Consensus Picks - Улправда
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies - Nasdaq
Sentiment Review: Why Ionis Pharmaceuticals Inc. stock could see breakout soon - Улправда
Why Ionis Pharmaceuticals Inc. stock is a value investor pickTrade Exit Report & Risk Adjusted Buy/Sell Alerts - Улправда
Ionis Pharmaceuticals stock hits 52-week high at 83.62 USD By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals (IONS) Is Up 5.1% After Hepatitis B Drug Hits Phase 3 GoalsHas The Bull Case Changed? - Sahm
Why Ionis Pharmaceuticals (IONS) Is Up 5.1% After Hepatitis B Drug Hits Phase 3 Goals And What's Next - Yahoo Finance
GSK’s hep B approach hits functional cure goal in pivotal trials - BioWorld MedTech
GSK Gets Closer to Bringing Patients a Functional Cure for Chronic Hepatitis B - MedCity News
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies - Benzinga
GSK, Ionis claim study success for RNA-based hepatitis B drug - BioPharma Dive
Ionis Pharmaceuticals (NASDAQ:IONS) Reaches New 52-Week HighHere's Why - MarketBeat
Ionis Pharmaceuticals stock hits 52-week high at 83.62 USD - Investing.com
Hepatitis B Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Arbutus Biopharma, GSK/Ionis Pharma, Vir Biotech, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp - The Globe and Mail
Hepatitis B Market to Witness Promising Upswing by 2034, - openPR.com
GSK Scores An R&D Win With Bepirovirsen Phase III Hep B Data - Citeline News & Insights
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B - BioSpace
Ionis Pharmaceuticals Announces Positive Phase 3 Results for Bepirovirsen - TradingView — Track All Markets
GSK’s hepatitis B drug shows positive results in phase 3 trials - Investing.com Canada
Ionis Pharmaceuticals Inc Stock Analysis and ForecastEarnings Volatility Patterns & Budget Friendly Capital Growth - earlytimes.in
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies - Bitget
Ionis Pharmaceuticals EVP Research Sells Shares - TradingView — Track All Markets
Treatment-resistant Hypertension Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Idorsia Pharma, Ionis Pharma, KBP Biosciences, KBP Biosciences, Quantum Genomics - Barchart.com
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference - MEXC
Ionis to present at 44th Annual JP Morgan Healthcare Conference - FinancialContent
Nucleic Acid Therapeutics Market to Reach US$ 14.42 Billion - openPR.com
Assessing Ionis Pharmaceuticals (IONS) Valuation After Analyst Optimism And FDA Approval Of Tryngolza - Sahm
Ionis Pharmaceuticals Inc (IONS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):